Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The zoonosis caused by is increasing seriously. But commonly used antibiotic drugs often lead to resistance. dUTPase (dUTPase) plays a key role in the proliferation of , and was regarded as a potent drug target. However, there was little report about the dUTPase inhibitors. In this study, we discovered a series of novel dUTPase inhibitors to fight against . The first crystal structure of dUTPase was released, and a structure-based computational design was performed. Compounds and exhibited promising activities towards dUTPase (IC = 0.99 μM and 0.7 μM). In addition, they showed satisfied anti- activity (MIC value ranges from 0.5 to 2 mg/L) and low cytotoxicity, which were better than approved drugs oxytetracycline and florfenicol. Molecular modelling study indicated that hydrophobic interaction might be the main contribution for ligand binding. Our results suggested that dUTPase inhibitors might be a useful way to repress .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486130 | PMC |
| http://dx.doi.org/10.1080/14756366.2024.2411573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Full-length inhibitor protein is the most effective to perturb human dUTPase activity.
Sci Rep
February 2025
Department of Applied Biotechnology and Food Science, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, 111, Hungary.
It has been demonstrated recently that knockout of the dUTPase enzyme leads to early embryonic lethality in mice. However, to explore the physiological processes arising upon the lack of dUTPase an effective and selective enzyme inhibitor is much needed. A highly specific and strong binding proteinaceous human dUTPase inhibitor described by us recently was a promising starting point to develop a molecular tool to study temporal and conditional dUTPase inhibition in cellulo.
View Article and Find Full Text PDFStructure-guided discovery of novel dUTPase inhibitors with anti- activity by computational design.
J Enzyme Inhib Med Chem
December 2024
School of Life Sciences, State Key Laboratory of Biocatalysis and Enzyme Engineering, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei University, Wuhan, PR China.
Article Synopsis
- Zoonotic infections are on the rise, but commonly used antibiotics are leading to resistance, highlighting the need for new treatment strategies.
- The study identifies novel inhibitors of dUTPase, an important enzyme for pathogen proliferation, with promising effectiveness against the target organism and lower toxicity than existing antibiotics.
- Molecular modeling suggests that hydrophobic interactions are key to how these inhibitors bind to dUTPase, indicating a potential new avenue for developing treatments against zoonosis.
In-silico evaluation of Oroxylum indicum vent compounds in the plausible treatment and prevention of nasopharyngeal cancer.
J Ayurveda Integr Med
May 2024
Central Council for Research in Ayurvedic Sciences, Ministry of Ayush, India.
Background: Shyonaka (Oroxylum indicum Vent) is widely used in Ayurveda and in ethnomedical practice for the treatment of inflammation, pain, diarrhea, non-healing ulcers, and cancer. Owing to the high prevalence of Epstein-Barr virus (EBV) infection in Nasopharyngeal carcinoma (NPC) patients, simultaneous targeting of proteins involved in both EBV replication and NPC proliferation might help to manage the disease effectively.
Objectives: This study is designed to identify potential dual targeting inhibitors from Oroxylum indicum having the potential to inhibit both EBV and NPC.
Synthesis and characterisation of a nucleotide based pro-drug formulated with a peptide into a nano-chemotherapy for colorectal cancer.
J Control Release
May 2024
School of Pharmacy, Queen's University Belfast, Medical Biological Centre, 97 Lisburn Road, Belfast BT9 7LB, UK; School of Chemical Sciences, Dublin City University, Collins Avenue, Dublin 9, Ireland. Electronic address:
Recent studies in colorectal cancer patients (CRC) have shown that increased resistance to thymidylate synthase (TS) inhibitors such as 5-fluorouracil (5-FU), reduce the efficacy of standard of care (SoC) treatment regimens. The nucleotide pool cleanser dUTPase is highly expressed in CRC and is an attractive target for potentiating anticancer activity of chemotherapy. The purpose of the current work was to investigate the activity of P, P-di(2',5'-dideoxy-5'-selenouridinyl)-tetraphosphate (P-SedU), a selenium-modified symmetrically capped dinucleoside with prodrug capabilities that is specifically activated by dUTPase.
View Article and Find Full Text PDFMedicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer.
Drug Discov Today
January 2024
Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda 151401, India. Electronic address:
Deoxyuridine-5'-triphosphate nucleotidohydrolase (dUTPase), a vital enzyme in pyrimidine metabolism, is a prime target for treating colorectal cancer. Uracil shares structural traits with DNA/RNA bases, prompting exploration by medicinal chemists for pharmacological modifications. Some existing drugs, including thymidylate synthase (TS) and dUTPase inhibitors, incorporate uracil moieties.
View Article and Find Full Text PDF